glyph (Photo: Getty Images)
Experts and scientists are working tirelessly to discover a cure for cancer, and this time, researchers claim to have taken a step forward in preventing men against the most common kind of cancer, prostate cancer.
According to recent studies, the treatment, which will be branded Pluvicto, has the potential to extend the lives of prostate cancer patients by at least four months.
The Medicines and Healthcare Products Regulatory Agency has approved the drug for usage, according to the British tabloid Daily Mail.
According to Johan de Bono, Professor of Experimental Cancer Medicine at the Institute of Cancer Research London, this is a significant advancement in the battle against one of the most fatal tumours in men, and it is also a potential treatment for other forms of cancer.
PSMA, a protein found on the surface of prostate cancer cells, is the target of a Novartis drug.
The therapy works similarly to a guided missile in that it identifies cancer cells in the body and delivers a radioactive payload to destroy them.
According to Joseph Woolcott of the Institute of Prostate Cancer UK, men with advanced prostate cancer have few therapy alternatives.
A new cancer treatment protects men from the most fatal kind of cancer.
About Author
